• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMEA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Erdtmann Rainer M

    (Last) (First) (Middle)
    C/O BIOMEA FUSION, INC.
    1599 INDUSTRIAL ROAD

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Biomea Fusion, Inc. [ BMEA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    11/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/28/2025 P 40,000 A $1.1013(1) 683,027 D
    Common Stock 12/01/2025 P 10,000 A $1.05 693,027 D
    Common Stock 19,400 I By daughter
    Common Stock 20,000 I By son
    Common Stock 20,000 I By daughter
    Common Stock 174,614 I See Footnote(2)
    Common Stock 1,134,989 I See Footnote(3)
    Common Stock 228,470 I See Footnote(4)
    Common Stock 252,320 I See Footnote(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.1099, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
    2. The shares are held by a trust having an independent trustee ("Trust 1"). The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
    3. The shares are held by a trust having an independent trustee ("Trust 2"). The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
    4. The shares are held directly by Point Sur Investors Fund I, LP ("Point Sur LP"). The General Partner of Point Sur LP is Point Sur Investors LLC. The Reporting Person is a managing member of Point Sur Investors, LLC and as such has voting and dispositive power over the securities held by Point Sur LP. The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
    5. The shares are held directly by Point Sur Investors, LLC. The Reporting Person is a managing members of Point Sur Investors, LLC and as such has voting and dispositive power over the securities held by Point Sur Investors, LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
    Remarks:
    President, Chief Operating Officer, Principal Financial Officer, and Principal Accounting Officer
    /s/ Rainer M. Erdtmann 12/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BMEA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMEA

    DatePrice TargetRatingAnalyst
    8/28/2025$5.00Buy
    Jefferies
    6/3/2025$7.00Overweight
    Piper Sandler
    10/9/2024$128.00Buy
    Edward Jones
    9/27/2024$18.00Neutral → Buy
    Rodman & Renshaw
    9/27/2024$54.00Hold → Buy
    Truist
    8/29/2024$25.00Overweight
    CapitalOne
    6/11/2024Buy → Hold
    Truist
    6/7/2024$30.00 → $5.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

    Key Opinion Leader, Dr. Ralph DeFronzo presents the "Future of Menin Inhibitors" and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio. The interview highlights the growing body of preclinical and clinical findings supporting the use of icovamenib in patient

    12/9/25 6:35:22 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic and c-peptide improvements with icovamenib, a menin inhibitor targeting beta-cell restoration in insulin deficient type 2 diabetes. "I am very pleased that our data was selected for an oral presentation at the WCIRDC meeting this year. Over the past 24 months, our clinical studies have shown that selective inhibition of menin can meani

    12/5/25 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments from both emerging investigators and world-renowned leaders. "We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabet

    12/1/25 4:10:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Biomea Fusion Inc.

    SCHEDULE 13G - Biomea Fusion, Inc. (0001840439) (Subject)

    12/8/25 11:44:21 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biomea Fusion Inc.

    SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    11/7/25 4:48:26 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Biomea Fusion Inc.

    10-Q - Biomea Fusion, Inc. (0001840439) (Filer)

    11/4/25 4:09:19 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Interim CEO Hitchcock Michael J.M.

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    8/13/25 4:15:10 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Biomea Fusion with a new price target

    Jefferies initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $5.00

    8/28/25 8:09:13 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on Biomea Fusion with a new price target

    Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00

    6/3/25 7:31:50 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edward Jones initiated coverage on Biomea Fusion with a new price target

    Edward Jones initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $128.00

    10/9/24 8:20:08 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Financials

    Live finance-specific insights

    View All

    Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

    Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo adjusted mean reduction in HbA1c (Arm B)Type 2 diabetes patients on a GLP-1-based therapy failing to achieve their target HbA1c also showed a clinically meaningful response from only 12 weeks of icovamenib treatment with a mean placebo adjusted HbA1c reduction of 1.8% (Arms A, B, and C combined) at Week 52Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Phase II trials

    10/6/25 4:03:07 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

    Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company

    12/17/24 8:10:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

    REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes. Conference Call and Webcast Details Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to reg

    12/16/24 6:15:01 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    10/1/24 4:30:12 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

    SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    11/12/24 12:31:45 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

    SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    7/10/24 6:39:58 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Biomea Fusion Inc.

    SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)

    4/10/24 9:45:50 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Leadership Updates

    Live Leadership Updates

    View All

    Biomea Fusion Appoints Julianne Averill to its Board of Directors

    SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her prov

    7/24/25 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

    Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

    5/5/25 4:05:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

    Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

    3/31/25 4:10:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care